EQL Pharma AB publishes prospectus for list change to Nasdaq Stockholm

EQL Pharma AB ("EQL Pharma" or the "Company") announced on 12 June 2024 that Nasdaq Stockholm’s listing committee has approved that the Company’s shares are admitted to trading on Nasdaq Stockholm Main Market. The prospectus that has been prepared in connection with the list change has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is now available on EQL Pharma’s website, www.eqlpharma.com, and will be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.

A listing of the Company’s shares on Nasdaq Stockholm is an important step in EQL Pharma’s continued development and gives the Company further access to the Swedish and international capital markets. EQL Pharma has been listed on Spotlight Stock Market since 2013, but the board of directors believes that the listing of the Company’s share on Nasdaq Stockholm will increase the conditions for broadening EQL Pharma’s shareholder base and give the Company access to additional international and institutional investors, which is deemed to promote the Company’s continued development. Furthermore, the listing also carries a quality stamp for EQL Pharma and its operations.

EQL Pharma’s shares will be traded in the Small Cap segment under the ticker EQL and ISIN code SE0005497732. There will be no offering to subscribe for or otherwise acquire new shares in connection with the list change. Shareholders in EQL Pharma do not need to take any actions. The first day of trading on Nasdaq Stockholm Main Market is Thursday 4 July 2024 and the last day of trading on Spotlight Stock Market is Wednesday 3 July 2024.

Advisors

Setterwalls Advokatbyrå AB is acting as legal advisor to EQL Pharma in connection with the listing.